| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:1672.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Department of Medicine (N.W.M., P.D.U.), University of Cambridge School of Clinical Medicine, Addenbrookes Hospital, Cambridge, UK; Department of Pathology (C.A., S.S.), Papworth Hospital, Cambridge, UK; and Division of Medical Genetics (R.M., J.R.T., R.C.T.), University of Leicester, Leicester, UK.
Correspondence to Dr Nicholas W. Morrell, Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrookes Hospital, Box 157, Hills Rd, Cambridge CB2 2QQ, UK. E-mail nwm23{at}cam.ac.uk
Background Mutations in the type II receptor for bone morphogenetic protein (BMPR-II), a receptor member of the transforming growth factor-ß (TGF-ß) superfamily, underlie many familial and sporadic cases of primary pulmonary hypertension (PPH).
Methods and Results Because the sites of expression of BMPR-II in the normal and hypertensive lung are unknown, we studied the cellular localization of BMPR-II and the related type I and II receptors for TGF-ß by immunohistochemistry in lung sections from patients undergoing heart-lung transplantation for PPH (n=11, including 3 familial cases) or secondary pulmonary hypertension (n=6) and from unused donor lungs (n=4). In situ hybridization was performed for BMPR-II mRNA. Patients were screened for the presence of mutations in BMPR2. In normal lungs, BMPR-II expression was prominent on vascular endothelium, with minimal expression in airway and arterial smooth muscle. In pulmonary hypertension cases, the intensity of BMPR-II immunostaining varied between lesions but involved endothelial and myofibroblast components. Image analysis confirmed that expression of BMPR-II was markedly reduced in the peripheral lung of PPH patients, especially in those harboring heterozygous BMPR2 mutations. A less marked reduction was also observed in patients with secondary pulmonary hypertension. In contrast, there was no difference in level of staining for TGF-ßRII or the endothelial marker CD31.
Conclusions The cellular localization of BMPR-II is consistent with a role in the formation of pulmonary vascular lesions in PPH, and reduced BMPR-II expression may contribute to the process of vascular obliteration in severe pulmonary hypertension.
Key Words: hypertension, pulmonary immunohistochemistry receptors
This article has been cited by other articles:
![]() |
K.-H. Hong, Y. J. Lee, E. Lee, S. O. Park, C. Han, H. Beppu, E. Li, M. K. Raizada, K. D. Bloch, and S. P. Oh Genetic Ablation of the Bmpr2 Gene in Pulmonary Endothelium Is Sufficient to Predispose to Pulmonary Arterial Hypertension Circulation, August 12, 2008; 118(7): 722 - 730. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Sztrymf, F. Coulet, B. Girerd, A. Yaici, X. Jais, O. Sitbon, D. Montani, R. Souza, G. Simonneau, F. Soubrier, et al. Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of BMPR2 Mutation Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1377 - 1383. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yang, R. J. Davies, M. Southwood, L. Long, X. Yang, A. Sobolewski, P. D. Upton, R. C. Trembath, and N. W. Morrell Mutations in Bone Morphogenetic Protein Type II Receptor Cause Dysregulation of Id Gene Expression in Pulmonary Artery Smooth Muscle Cells: Implications for Familial Pulmonary Arterial Hypertension Circ. Res., May 23, 2008; 102(10): 1212 - 1221. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ray, M. Mathieu, P. Jespers, I. Hadad, M. Mahmoudabady, A. Pensis, S. Motte, I. R. Peters, R. Naeije, and K. McEntee Early increase in pulmonary vascular reactivity with overexpression of endothelin-1 and vascular endothelial growth factor in canine experimental heart failure Exp Physiol, March 1, 2008; 93(3): 434 - 442. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Asosingh, M. A. Aldred, A. Vasanji, J. Drazba, J. Sharp, C. Farver, S. A.A. Comhair, W. Xu, L. Licina, L. Huang, et al. Circulating Angiogenic Precursors in Idiopathic Pulmonary Arterial Hypertension Am. J. Pathol., March 1, 2008; 172(3): 615 - 627. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Newman, J. A. Phillips III, and J. E. Loyd Narrative Review: The Enigma of Pulmonary Arterial Hypertension: New Insights from Genetic Studies Ann Intern Med, February 19, 2008; 148(4): 278 - 283. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Yu, D. Y. Deng, H. Beppu, C. C. Hong, C. Lai, S. A. Hoyng, N. Kawai, and K. D. Bloch Bone Morphogenetic Protein (BMP) Type II Receptor Is Required for BMP-mediated Growth Arrest and Differentiation in Pulmonary Artery Smooth Muscle Cells J. Biol. Chem., February 15, 2008; 283(7): 3877 - 3888. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Ramos, M. W. Lame, H. J. Segall, and D. W. Wilson Smad Signaling in the Rat Model of Monocrotaline Pulmonary Hypertension Toxicol Pathol, February 1, 2008; 36(2): 311 - 320. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D. Upton, L. Long, R. C. Trembath, and N. W. Morrell Functional Characterization of Bone Morphogenetic Protein Binding Sites and Smad1/5 Activation in Human Vascular Cells Mol. Pharmacol., February 1, 2008; 73(2): 539 - 552. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Frank, J. Lowery, L. Anderson, M. Brink, J. Reese, and M. de Caestecker Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature Am J Physiol Lung Cell Mol Physiol, January 1, 2008; 294(1): L98 - L109. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Lagna, M. M. Ku, P. H. Nguyen, N. A. Neuman, B. N. Davis, and A. Hata Control of Phenotypic Plasticity of Smooth Muscle Cells by Bone Morphogenetic Protein Signaling through the Myocardin-related Transcription Factors J. Biol. Chem., December 21, 2007; 282(51): 37244 - 37255. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Sanchez, E. Marcos, F. Perros, E. Fadel, L. Tu, M. Humbert, P. Dartevelle, G. Simonneau, S. Adnot, and S. Eddahibi Role of Endothelium-derived CC Chemokine Ligand 2 in Idiopathic Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., November 15, 2007; 176(10): 1041 - 1047. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. Masri, W. Xu, S. A. A. Comhair, K. Asosingh, M. Koo, A. Vasanji, J. Drazba, B. Anand-Apte, and S. C. Erzurum Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L548 - L554. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Liu, J. Wang, B. Kinzel, M. Mueller, X. Mao, R. Valdez, Y. Liu, and E. Li Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrity Blood, September 1, 2007; 110(5): 1502 - 1510. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Morty, B. Nejman, G. Kwapiszewska, M. Hecker, A. Zakrzewicz, F. M. Kouri, D. M. Peters, R. Dumitrascu, W. Seeger, P. Knaus, et al. Dysregulated Bone Morphogenetic Protein Signaling in Monocrotaline-Induced Pulmonary Arterial Hypertension Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1072 - 1078. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Reynolds, W. Xia, M. D. Holmes, S. J. Hodge, S. Danilov, D. T. Curiel, N. W. Morrell, and P. N. Reynolds Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1182 - L1192. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. McMurtry, R. Moudgil, K. Hashimoto, S. Bonnet, E. D. Michelakis, and S. L. Archer Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, April 1, 2007; 292(4): L872 - L878. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. LeClair, T. Durmus, Q. Wang, P. Pyagay, A. Terzic, and V. Lindner Cthrc1 Is a Novel Inhibitor of Transforming Growth Factor-{beta} Signaling and Neointimal Lesion Formation Circ. Res., March 30, 2007; 100(6): 826 - 833. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. I. Said, S. A. Hamidi, K. G. Dickman, A. M. Szema, S. Lyubsky, R. Z. Lin, Y.-P. Jiang, J. J. Chen, J. A. Waschek, and S. Kort Moderate Pulmonary Arterial Hypertension in Male Mice Lacking the Vasoactive Intestinal Peptide Gene Circulation, March 13, 2007; 115(10): 1260 - 1268. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. W. Morrell Pulmonary Hypertension Due to BMPR2 Mutation: A New Paradigm for Tissue Remodeling? Proceedings of the ATS, November 1, 2006; 3(8): 680 - 686. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Fantozzi, O. Platoshyn, A. H. Wong, S. Zhang, C. V. Remillard, M. R. Furtado, O. V. Petrauskene, and J. X.-J. Yuan Bone morphogenetic protein-2 upregulates expression and function of voltage-gated K+ channels in human pulmonary artery smooth muscle cells Am J Physiol Lung Cell Mol Physiol, November 1, 2006; 291(5): L993 - L1004. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. I. Said Mediators and modulators of pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L547 - L558. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wu, M. S. Chang, S. A. Mitsialis, and S. Kourembanas Hypoxia Regulates Bone Morphogenetic Protein Signaling Through C-Terminal-Binding Protein 1 Circ. Res., August 4, 2006; 99(3): 240 - 247. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Takahashi, N. Goto, Y. Kojima, Y. Tsuda, Y. Morio, M. Muramatsu, and Y. Fukuchi Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, March 1, 2006; 290(3): L450 - L458. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Teichert-Kuliszewska, M. J.B. Kutryk, M. A. Kuliszewski, G. Karoubi, D. W. Courtman, L. Zucco, J. Granton, and D. J. Stewart Bone Morphogenetic Protein Receptor-2 Signaling Promotes Pulmonary Arterial Endothelial Cell Survival: Implications for Loss-of-Function Mutations in the Pathogenesis of Pulmonary Hypertension Circ. Res., February 3, 2006; 98(2): 209 - 217. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Rondelet, F. Kerbaul, R. Van Beneden, I. Hubloue, S. Huez, P. Fesler, M. Remmelink, S. Brimioulle, I. Salmon, and R. Naeije Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2319 - H2324. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Yu, H. Beppu, N. Kawai, E. Li, and K. D. Bloch Bone Morphogenetic Protein (BMP) Type II Receptor Deletion Reveals BMP Ligand-specific Gain of Signaling in Pulmonary Artery Smooth Muscle Cells J. Biol. Chem., July 1, 2005; 280(26): 24443 - 24450. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Kielstein, S. M. Bode-Boger, G. Hesse, J. Martens-Lobenhoffer, A. Takacs, D. Fliser, and M. M. Hoeper Asymmetrical Dimethylarginine in Idiopathic Pulmonary Arterial Hypertension Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1414 - 1418. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Stewart Bone Morphogenetic Protein Receptor-2 and Pulmonary Arterial Hypertension: Unraveling a Riddle Inside an Enigma? Circ. Res., May 27, 2005; 96(10): 1033 - 1035. [Full Text] [PDF] |
||||
![]() |
X. Yang, L. Long, M. Southwood, N. Rudarakanchana, P. D. Upton, T. K. Jeffery, C. Atkinson, H. Chen, R. C. Trembath, and N. W. Morrell Dysfunctional Smad Signaling Contributes to Abnormal Smooth Muscle Cell Proliferation in Familial Pulmonary Arterial Hypertension Circ. Res., May 27, 2005; 96(10): 1053 - 1063. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Machado, V. James, M. Southwood, R. E. Harrison, C. Atkinson, S. Stewart, N. W. Morrell, R. C. Trembath, and M. A. Aldred Investigation of Second Genetic Hits at the BMPR2 Locus as a Modulator of Disease Progression in Familial Pulmonary Arterial Hypertension Circulation, February 8, 2005; 111(5): 607 - 613. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. K. Jeffery, P. D. Upton, R. C. Trembath, and N. W. Morrell BMP4 inhibits proliferation and promotes myocyte differentiation of lung fibroblasts via Smad1 and JNK pathways Am J Physiol Lung Cell Mol Physiol, February 1, 2005; 288(2): L370 - L378. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Satoh, K. Kimura, Y. Okano, M. Hirakata, Y. Kawakami, and M. Kuwana Lack of circulating autoantibodies to bone morphogenetic protein receptor-II or activin receptor-like kinase 1 in mixed connective tissue disease patients with pulmonary arterial hypertension Rheumatology, February 1, 2005; 44(2): 192 - 196. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Richter, M. E. Yeager, A. Zaiman, C. D. Cool, N. F. Voelkel, and R. M. Tuder Impaired Transforming Growth Factor-{beta} Signaling in Idiopathic Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1340 - 1348. [Abstract] [Full Text] [PDF] |
||||
![]() |
R Koehler, E Grunig, M W Pauciulo, M M Hoeper, H Olschewski, H Wilkens, M Halank, J Winkler, R Ewert, H Bremer, et al. Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension J. Med. Genet., December 1, 2004; 41(12): e127 - e127. [Full Text] [PDF] |
||||
![]() |
H. Beppu, F. Ichinose, N. Kawai, R. C. Jones, P. B. Yu, W. M. Zapol, K. Miyazono, E. Li, and K. D. Bloch BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia Am J Physiol Lung Cell Mol Physiol, December 1, 2004; 287(6): L1241 - L1247. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kunichika, J. W. Landsberg, Y. Yu, H. Kunichika, P. A. Thistlethwaite, L. J. Rubin, and J. X.-J. Yuan Bosentan Inhibits Transient Receptor Potential Channel Expression in Pulmonary Vascular Myocytes Am. J. Respir. Crit. Care Med., November 15, 2004; 170(10): 1101 - 1107. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.B.W.E.M. Roos, G. Pals, P.M. Struycken, G.J.E. Rinkel, M. Limburg, J.C. Pronk, J.S.P. van den Berg, J.A.F.M. Luijten, P.L. Pearson, M. Vermeulen, et al. Genome-Wide Linkage in a Large Dutch Consanguineous Family Maps a Locus for Intracranial Aneurysms to Chromosome 2p13 Stroke, October 1, 2004; 35(10): 2276 - 2281. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yu, I. Fantozzi, C. V. Remillard, J. W. Landsberg, N. Kunichika, O. Platoshyn, D. D. Tigno, P. A. Thistlethwaite, L. J. Rubin, and J. X.-J. Yuan Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension PNAS, September 21, 2004; 101(38): 13861 - 13866. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Takeda, F. Otsuka, K. Nakamura, K. Inagaki, J. Suzuki, D. Miura, H. Fujio, H. Matsubara, H. Date, T. Ohe, et al. Characterization of the Bone Morphogenetic Protein (BMP) System in Human Pulmonary Arterial Smooth Muscle Cells Isolated from a Sporadic Case of Primary Pulmonary Hypertension: Roles of BMP Type IB Receptor (Activin Receptor-Like Kinase-6) in the Mitotic Action Endocrinology, September 1, 2004; 145(9): 4344 - 4354. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Doherty, L. A. Fitzpatrick, D. Inoue, J.-H. Qiao, M. C. Fishbein, R. C. Detrano, P. K. Shah, and T. B. Rajavashisth Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification Endocr. Rev., August 1, 2004; 25(4): 629 - 672. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Humbert, N. W. Morrell, S. L. Archer, K. R. Stenmark, M. R. MacLean, I. M. Lang, B. W. Christman, E. K. Weir, O. Eickelberg, N. F. Voelkel, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 13S - 24S. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Newman, R. C. Trembath, J. A. Morse, E. Grunig, J. E. Loyd, S. Adnot, F. Coccolo, C. Ventura, J. A. Phillips III, J. A. Knowles, et al. Genetic basis of pulmonary arterial hypertension: Current understanding and future directions J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 33S - 39S. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. K. Weir, Z. Hong, and A. Varghese The Serotonin Transporter: A Vehicle to Elucidate Pulmonary Hypertension? Circ. Res., May 14, 2004; 94(9): 1152 - 1154. [Full Text] [PDF] |
||||
![]() |
E. Marcos, E. Fadel, O. Sanchez, M. Humbert, P. Dartevelle, G. Simonneau, M. Hamon, S. Adnot, and S. Eddahibi Serotonin-Induced Smooth Muscle Hyperplasia in Various Forms of Human Pulmonary Hypertension Circ. Res., May 14, 2004; 94(9): 1263 - 1270. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. West, K. Fagan, W. Steudel, B. Fouty, K. Lane, J. Harral, M. Hoedt-Miller, Y. Tada, J. Ozimek, R. Tuder, et al. Pulmonary Hypertension in Transgenic Mice Expressing a Dominant-Negative BMPRII Gene in Smooth Muscle Circ. Res., April 30, 2004; 94(8): 1109 - 1114. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Budhiraja, R. M. Tuder, and P. M. Hassoun Endothelial Dysfunction in Pulmonary Hypertension Circulation, January 20, 2004; 109(2): 159 - 165. [Full Text] [PDF] |
||||
![]() |
C. V. Remillard and J. X.-J. Yuan Activation of K+ channels: an essential pathway in programmed cell death Am J Physiol Lung Cell Mol Physiol, January 1, 2004; 286(1): L49 - L67. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Machado, N. Rudarakanchana, C. Atkinson, J. A. Flanagan, R. Harrison, N. W. Morrell, and R. C. Trembath Functional interaction between BMPR-II and Tctex-1, a light chain of Dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension Hum. Mol. Genet., December 15, 2003; 12(24): 3277 - 3286. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Blanpain, E. Le Poul, J. Parma, C. Knoop, M. Detheux, M. Parmentier, G. Vassart, and M. J Abramowicz Serotonin 5-HT2B receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension Cardiovasc Res, December 1, 2003; 60(3): 518 - 528. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Favre, M. Mancuso, K. Maas, J. W. McLean, P. Baluk, and D. M. McDonald Expression of genes involved in vascular development and angiogenesis in endothelial cells of adult lung Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H1917 - H1938. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zhang, I. Fantozzi, D. D. Tigno, E. S. Yi, O. Platoshyn, P. A. Thistlethwaite, J. M. Kriett, G. Yung, L. J. Rubin, and J. X.-J. Yuan Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells Am J Physiol Lung Cell Mol Physiol, September 1, 2003; 285(3): L740 - L754. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. N. Kao and J. L. Faul Emerging therapies for pulmonary hypertension: Striving for efficacy and safety J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2126 - 2129. [Full Text] [PDF] |
||||